<DOC>
	<DOCNO>NCT03033433</DOCNO>
	<brief_summary>An Open-Label Phase I Study Assess Safety Tolerability Profile Three Escalating Doses DCB-DM101 Healthy Volunteers Optimum Dose DCB-DM101 Add-on Treatment Type 2 Diabetes Mellitus ( T2DM ) Patients</brief_summary>
	<brief_title>DCB-DM101 Healthy Volunteers Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description>This single center , open-label , phase-I study consist two stage : Stage 1 dose-escalation study assess safety tolerability profile three escalate dos DCB-DM101 healthy volunteer Stage 2 apply optimum dose DCB-DM101 add-on treatment T2DM patient . In Stage 2 , patient allow receive metformin T2DM routine use dose regimen adjust . No medication/treatments T2DM allow . Stage 2 proceeded upon approval health authority Taiwan . After determine optimal dose Stage 2 , reason determine dose together relevant support data submit health authority Taiwan review determine whether stage 2 proceed dose employed stage 2 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Stage 1 1 . Adult , male female age 2040 year old ; 2 . Physically mentally healthy subject confirm interview , medical history , clinical examination , chest Xrays , electrocardiogram ; 3 . Body Mass Index ( BMI ) 18.5 24 , inclusive , ( BMI calculate weight kilogram [ kg ] /height meters2 [ m2 ] ) ; 4 . Clinically normal hematology , biochemistry urinalysis determination base investigator 's discretion ; 5 . Subject willing able comply study procedure sign inform consent . Stage 2 1 . Male female age 2070 year old ; 2 . Diagnosed T2DM ( WHO 1999 criterion ) ; 3 . Not effective alleviate T2DM monotherapy metformin 1,500mg/day [ 1,000mg/day unable tolerate high dose ] 3 month 4 . HbA1c 7.0 % 9.0 % ( inclusive ) ; 5 . BMI 35 kg/m2 ; 6 . Subject willing able comply study procedure sign inform consent Stage 1 1 . Subjects history evidence medical condition would expose undue risk significant adverse event interfere assessment safety pharmacodynamics variable course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine , immune , neurological , musculoskeletal hematological disease determine clinical judgment investigator ; 2 . Subject receive investigational agent within 28 day 5 halflives , whichever longer , prior first dose study drug ; 3 . Subjects take potentially take prescription medication and/or thecounter medication within 1 week prior first dose study drug end study period ; 4 . Subject alcohol , caffeine , grapefruit juice , nicotine consumption within 24 hour prior administration study drug ; 5 . Female subject childbearing potential : lactating ; positive urine pregnancy test Visit 1 ; refuse adopt least two form birth control ( least one must barrier method ) study . Stage 2 1 . Known suspected allergy ingredient study product 2 . Pregnant lactate premenopausal childbearing potential take least two form birth control ( least one must barrier method ) study . Note : Acceptable form include : 1 . Established use oral , injected implant hormonal method contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Condom OR Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . 3 . Participated another clinical trial receive investigational drug within four week prior present trial 4 . Impaired hepatic function define alanine aminotransferase ( ALT ) , aspartate transaminase ( AST ) alkaline phosphatase ( ALP ) least 2.5 time upper reference limit 5 . Impaired renal function define serumcreatinine least 1.3 mg/dL ( least 115 umol/L ) male least 1.2 mg/dL ( least 106 umol/L ) females 6 . With uncontrolled illness history illness judge investigator enter trial may detrimental subject 7 . Metformin contraindication accord package insert 8 . Current treatment systemic corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>